Purepac Patent Decision Leaves Certification Strategy To ANDA Applicant
Executive Summary
The Purepac court ruling on gabapentin leaves generic companies with a strategic decision of whether to seek a section viii statement or Paragraph IV certification when filing ANDAs against a patented product